Clinical Trial Update: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating DFF332 as a single agent and in combination with Everolimus and immuno-oncology agents in advanced/relapsed renal cell carcinoma has be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• DFF332
• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Renal Cell | Phase 1 | Status: TERMINATED